These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15879429)

  • 21. The determination of budesonide and fluticasone in human sputum samples collected from COPD patients using LC-MS/MS.
    Buscher BA; Jägfeldt H; Sandman H; Brust-van Schaik R; van Schaik F; Brüll LP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 880(1):6-11. PubMed ID: 22169057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related.
    Reid DW; Wen Y; Johns DP; Williams TJ; Ward C; Walters EH
    Respirology; 2008 Nov; 13(6):799-809. PubMed ID: 18811878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of nasal anti-inflammatory treatment in chronic obstructive pulmonary disease.
    Callebaut I; Hox V; Bobic S; Bullens DM; Janssens W; Dupont L; Hellings PW
    Am J Rhinol Allergy; 2013; 27(4):273-7. PubMed ID: 23883807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.
    Andò F; Ruggeri P; Girbino G; Cazzola M
    Respir Med; 2008 Jun; 102(6):815-8. PubMed ID: 18343646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.
    van den Boom G; Rutten-van Mölken MP; Molema J; Tirimanna PR; van Weel C; van Schayck CP
    Am J Respir Crit Care Med; 2001 Dec; 164(11):2057-66. PubMed ID: 11739135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The traditional herbal medicine Hochuekkito improves systemic inflammation in patients with chronic obstructive pulmonary disease.
    Shinozuka N; Tatsumi K; Nakamura A; Terada J; Kuriyama T
    J Am Geriatr Soc; 2007 Feb; 55(2):313-4. PubMed ID: 17302677
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis.
    Andréjak C; Nielsen R; Thomsen VØ; Duhaut P; Sørensen HT; Thomsen RW
    Thorax; 2013 Mar; 68(3):256-62. PubMed ID: 22781123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 31. [Debates surrounding COPD].
    Tillie-Leblond I; Housset B
    Rev Mal Respir; 2010 Feb; 27(2):106-7. PubMed ID: 20206057
    [No Abstract]   [Full Text] [Related]  

  • 32. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.
    Parnham MJ; Culić O; Eraković V; Munić V; Popović-Grle S; Barisić K; Bosnar M; Brajsa K; Cepelak I; Cuzić S; Glojnarić I; Manojlović Z; Novak-Mircetić R; Oresković K; Pavicić-Beljak V; Radosević S; Sucić M
    Eur J Pharmacol; 2005 Jul; 517(1-2):132-43. PubMed ID: 15964564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD.
    Van Overveld FJ; Demkow U; Górecka D; De Backer WA; Zieliński J
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 4():273-82. PubMed ID: 17072055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C; Petroianni A; Ricci A; Allegra L
    Eur Rev Med Pharmacol Sci; 2005; 9(4):209-15. PubMed ID: 16128040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation among the levels of C-reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease].
    Long H; Luo H; Chen P; Li Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1090-6. PubMed ID: 22169727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
    Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing mortality risk in COPD.
    Richie RC
    J Insur Med; 2008; 40(1):55-63. PubMed ID: 18924368
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.